Corporate costs cannot be extrapolated. If you read the 4C, $2.7m last quarter was non-recurring relating to the Imbio acquisition. In the Dec 2023 quarter, they would have incurred further non-recurring costs for the Imbio DD and agreements etc too.
Ann: Quarterly Activity Report and Appendix 4C for Q3 FY2024, page-25
Add 4DX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
-0.050(8.77%) |
Mkt cap ! $203.5M | |||
| Open | High | Low | Value | Volume |
| 57.0¢ | 57.0¢ | 51.5¢ | $1.080M | 2.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21197 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 4369 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| 4DX (ASX) Chart |